Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Advanced Non-Small Cell Lung Cancer
NCT00094094Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of axitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Objective Response Rate at 98 weeks. Started Feb 2005; status: completed.
02
Drugs
axitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00094094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094094.